

In the Specification at page 2 please replace the second paragraph with the following:

sub F  
D  
This application is a divisional of co-pending application Serial No. 08/889,108 filed on July 7, 1997, now U.S. Patent No. 6,103,492, which is a file-wrapper continuation of Serial No. 08/305,518 filed on September 13, 1994, now abandoned, which is a continuing application of Serial No. 08/120,601 filed September 13, 1993, now U.S. Patent No. 6,235,496, which is a continuing application of U.S. Serial No. 08/056,886 filed on March 8, 1993, now abandoned.

In the claims, please enter the follow amended claims:

- D<sup>2</sup>
44. (Amended three times) A process of screening a candidate substance for its ability to bind to a mu opioid receptor comprising:
- a) providing a recombinant mu opioid receptor polypeptide comprising the contiguous amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:8, or SEQ ID NO:17;
  - b) obtaining a candidate substance; and
  - c) testing the ability of said candidate substance to bind to said opioid receptor.
- D<sup>3</sup>
46. (Amended) The process of claim 44 wherein the step of testing the ability of the candidate substance to bind to the opioid receptor involves determining the binding affinity of the candidate substance to the receptor.
- D<sup>3</sup>
47. (Amended) The process of claim 44 wherein the step of testing the ability of the candidate substance to bind to the opioid receptor involves determining the intrinsic activation ability of the candidate substance for the receptor.
- D<sup>4</sup>
65. (Amended) A process for screening a candidate substance for its ability to bind to a mu opioid receptor comprising:
- (a) providing a recombinant opioid receptor polypeptide encoded by a nucleic acid sequence comprising at least 35 contiguous nucleotides of SEQ ID NO:7, including the guanine nucleotide at position 389 of SEQ ID NO:7;